Showing results (71-80 of 80) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Vascular Medicine (London, England)|July 12, 2018
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trialJeffrey S Berger, Beth L Abramson, Renato D Lopes, et al.Journal of the American College of Cardiology|December 22, 2018
Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID TrialCecilia C Low Wang, Juuso I Blomster, Gretchen Heizer, et al.Circulation|October 20, 2004
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trialsJames B Young, Mark E Dunlap, Marc A Pfeffer, et al.Circulation|September 1, 2016
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54)Marc P Bonaca, Shinya Goto, Deepak L Bhatt, et al.European Heart Journal|October 8, 2015
Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trialGiulia Magnani, Robert F Storey, Gabriel Steg, et al.Journal of the American College of Cardiology|April 6, 2016
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery DiseaseMarc P Bonaca, Deepak L Bhatt, Robert F Storey, et al.European Heart Journal|October 23, 2015
Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54Marc P Bonaca, Deepak L Bhatt, P Gabriel Steg, et al.JAMA Cardiology|July 21, 2016
Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 TrialMarc P Bonaca, Deepak L Bhatt, Ton Oude Ophuis, et al.Journal of the American College of Cardiology|February 7, 2018
Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary DiseaseSameer Bansilal, Marc P Bonaca, Jan H Cornel, et al.The New England Journal of Medicine|March 17, 2015
Long-term use of ticagrelor in patients with prior myocardial infarctionMarc P Bonaca, Deepak L Bhatt, Marc Cohen, et al.Pageof 8